机构

• 合肥物质科学研究院 [39]
• 上海药物研究所 [26]
• 近代物理研究所 [4]
• 金属研究所 [3]
• 上海生物化学与细胞生... [3]
• 上海营养与健康研究所 [2]
• 更多

采集方式

• OAI收割 [87]

内容类型

• 期刊论文 [87]

发表日期

• 2024 [3]
• 2023 [3]
• 2022 [11]
• 2021 [16]
• 2020 [18]
• 2019 [4]
• 更多

学科主题

• Oncology; ... [2]
• Biochemist... [1]
• Endocrinol... [1]
• Engineerin... [1]
• Oncology [1]

筛选

浏览/检索结果: 共87条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials 期刊论文  OAI收割 SCIENCE CHINA-LIFE SCIENCES, 2024 作者:  Wang, Jinliang;  Zhou, Wenyong;  Xu, Yu;  Duan, Jianchun;  Zhou, Qiaoxia   |  收藏  |  浏览/下载：2/0  |  提交时间：2024/11/20 non-squamous NSCLC  squamous NSCLC  LRP1B deleterious mutations  predictive biomarker  immune checkpoint inhibitor   The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity 期刊论文  OAI收割 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 卷号: 716, 页码: 12 作者:  Xuan, Yi-Fei;  Lu, Shan;  Ou, Ying-Jie;  Bao, Xu-Bin;  Huan, Xia-Juan   |  收藏  |  浏览/下载：12/0  |  提交时间：2024/07/12 MAT2A inhibitor  METTL3 inhibitor  m6A  Combination therapy  NSCLC   JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers 期刊论文  OAI收割 CANCER LETTERS, 2024, 卷号: 582, 页码: 15 作者:  Lu, Xuxiu;  Yu, Rilei;  Li, Zhen;  Yang, Mengke;  Dai, Jiajia   |  收藏  |  浏览/下载：31/0  |  提交时间：2024/04/07 Acquired resistance  Cancer  NSCLC  JC-010a  SHP2   Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells 期刊论文  OAI收割 LIFE SCIENCES, 2023, 卷号: 332, 页码: 10 作者:  Su, Ai-Ling;  Tian, Chang-Qing;  Ou, Ying-Jie;  Bao, Xu-Bin;  Huan, Xia-Juan   |  收藏  |  浏览/下载：22/0  |  提交时间：2023/12/08 CD73  Proteasome inhibitors  ERK  NSCLC   AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2023, 页码: 14 作者:  Pei, Jin-peng;  Wang, Yue;  Ma, Lan-ping;  Wang, Xin;  Liu, Liang   |  收藏  |  浏览/下载：31/0  |  提交时间：2023/04/10 AXL  NSCLC  TNBC  M2-macrophage  antibody-drug conjugate   Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：121/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Gefitinib enhances the anti-tumor immune response against EGFR-mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H 期刊论文  OAI收割 INTERNATIONAL JOURNAL OF ONCOLOGY, 2022, 卷号: 61 作者:  Guo, Huihui;  Zhang, Xilin;  Xie, Shangzhi;  Chen, Tianwei;  Xie, Dong   |  收藏  |  浏览/下载：109/0  |  提交时间：2022/12/22 gefitinib  CD28H  NSCLC  EGFR mutation   The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study 期刊论文  OAI收割 CANCER MEDICINE, 2022 作者:  Yu, Xiaoqing;  Si, Jinfei;  Wei, Jingwen;  Wang, Yanling;  Sun, Yan   |  收藏  |  浏览/下载：131/0  |  提交时间：2022/12/23 EGFR-TKIs  non-small cell lung cancer (NSCLC)  real-world study  survival outcome   The critical components for effective adaptive radiotherapy in patients with unresectable non-small-cell lung cancer: who, when and how 期刊论文  OAI收割 FUTURE ONCOLOGY, 2022 作者:  Zhou, Suna;  Meng, Yinnan;  Sun, Xuefeng;  Jin, Zhicheng;  Feng, Wei   |  收藏  |  浏览/下载：42/0  |  提交时间：2022/12/22 ART  how  NSCLC  when  who   Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety 期刊论文  OAI收割 JOURNAL OF THORACIC DISEASE, 2022 作者:  Shao, Lan;  Lou, Guangyuan   |  收藏  |  浏览/下载：25/0  |  提交时间：2022/12/22 Neoadjuvant  immunotherapy  immune-checkpoint inhibitors  non-small cell lung cancer (NSCLC)